GlassScriptPhysician profile
Anne G Coleman
NPI 1114938826
$3,794.80
in general payments reported to CMS, 2019-2025
28 companies · $676 in 2025
The $676 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $409 · 2021: $233 · 2022: $260 · 2023: $683 · 2024: $837 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $713.17 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $605.40 | 2019-2022 | |
| Abbott Laboratories | $439.94 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $415.55 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Idorsia Pharmaceuticals US INC | $215.30 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.21 | 2019-2024 | Xifaxan |
| Ibsa Pharma INC. | $178.85 | 2019-2025 | Tirosint, Licart, Tirosint |
| Dexcom, INC. | $141.90 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $140.79 | 2023-2025 | |
| Therapeuticsmd, INC. | $135.32 | 2019-2020 | |
| Bausch Health US, LLC | $82.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.39 | 2024-2025 | |
| Corcept Therapeutics | $72.58 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.54 | 2019-2025 | Ofev |
| Exact Sciences Corporation | $38.95 | 2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.89 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $36.39 | 2021 | |
| Amneal Pharmaceuticals LLC | $33.07 | 2025 | Unithroid |
| Romark Laboratories, Lc | $28.48 | 2019-2020 | |
| Novo Nordisk INC | $27.79 | 2020-2023 | Ozempic, Rybelsus |
| Genentech USA, INC. | $20.20 | 2020 | |
| Millicent US INC | $20.12 | 2020 | |
| Eisai INC. | $18.68 | 2020 | |
| Boston Scientific Corporation | $18.59 | 2025 | Watchman Flx |
| Currax Pharmaceuticals LLC | $14.49 | 2024 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $14.33 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.